Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cancer Genomic Medicine for Urological Malignancies in Japan.

International journal of urology : official journal of the Japanese Urological Association - 1 Apr 2026

Sato Yusuke, Fujii Yoichi, Kume Haruki

Abstract excerpt

Cancer is a disease caused by genomic alterations, and identifying the profile of genetic changes in each cancer leads to the optimal choice of treatment, that is, precision medicine. In Japan, comprehensive genomic profiling tests were covered by insurance in June 2019, and cancer genomic medicine was fully implemented in clinical practice. In the field of urological malignancies, the approval of olaparib for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Phthalazines
Share to Piperazines
Share to Precision Medicine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Testing

Share to Genomics

Share to Mutation

Share to Urologic Neoplasms

Source

Identifiers

PMID: 41928709
DOI: 10.1111/iju.70449

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cancer Genomic Medicine for Urological Malignancies in Japan.PMID 41928709Read ↗

The Current Status of Comprehensive Genomic Profiling in the Management of Metastatic Castration-Resistant Prostate Cancer: A Study from a Cooperative Hospital for Cancer Genomic Medicine in Japan.Semantic proximity Read ↗

Cancer genomic medicine in JapanSemantic proximity Read ↗

Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTCSemantic proximity Read ↗

GENOMICS OF PROSTATE CANCER: CLINICAL UTILITY AND CHALLENGES.Semantic proximity Read ↗

A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancerSemantic proximity Read ↗

Genetic testing for the clinician in prostate cancer.Semantic proximity Read ↗

Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancerSemantic proximity Read ↗

Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance.Semantic proximity Read ↗

Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer.Semantic proximity Read ↗

Genomic Profiling of Prostate Cancer: An Updated ReviewSemantic proximity Read ↗

[Molecular diagnostics and molecular tumor board in uro-oncology : Precision medicine using the example of metastatic castration-resistant prostate cancer].Semantic proximity Read ↗

Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.